VEGF Trap for the treatment of malignant ascites

被引：16

作者：

Becker, Gerhild ^{[1
]}

Blum, Hubert E. ^{[2
]}

机构：

[1] Univ Hosp Freiburg, Dept Palliat Care, D-79106 Freiburg, Germany

[2] Univ Hosp Freiburg, Dept Internal Med 2, D-79106 Freiburg, Germany

来源：

LANCET ONCOLOGY | 2012年 / 13卷 / 02期

关键词：

D O I：

10.1016/S1470-2045(11)70394-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：115 / 116

页数：3

共 8 条

[1] Malignant ascites: Past, present, and future [J].

Adam, RA ;

Adam, YG .

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (06) :999-1011

[2] Malignant ascites: Systematic review and guideline for treatment [J].

Becker, G ;

Galandi, D ;

Blum, HE .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (05) :589-597

[3] A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites [J].

Colombo, Nicoletta ;

Mangili, Giorgia ;

Mammoliti, Serafina ;

Kalling, Marten ;

Tholander, Bengt ;

Sternas, Lars ;

Buzenet, Giliane ;

Chamberlain, Donald .

GYNECOLOGIC ONCOLOGY, 2012, 125 (01) :42-47

[4]

Committee on Comparative Effectiveness Research Priorization. Board on Health Care Services, 2009, IN NAT PRIOR COMP EF, P2

[5]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[6] MECHANISMS OF MALIGNANT ASCITES PRODUCTION [J].

GARRISON, RN ;

GALLOWAY, RH ;

HEUSER, LS .

JOURNAL OF SURGICAL RESEARCH, 1987, 42 (02) :126-132

[7] Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study [J].

Gotlieb, Walter H. ;

Amant, Frederic ;

Advani, Suresh ;

Goswami, Chanchal ;

Hirte, Hal ;

Provencher, Diane ;

Somani, Naresh ;

Yamada, S. Diane ;

Tamby, Jean-Francois ;

Vergote, Ignace .

LANCET ONCOLOGY, 2012, 13 (02) :154-162

[8]

Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497

← 1 →